There are always updates on the card such as for the ongoing NK-trial, the upcoming CDH 17 ph1 start and of course the highly anticipated CLTX CAR-T Brain cancer ph 1 read out by end of this year. But I agree that in the current market climate only news that suggest a deal opportunity will drive the sp up.
Would rather have seen Bell Potter driving the sp to 10c and then a raise but we now got 4c and have to adjust to that level. If they get outstanding data then the MC will easily go above $ 100m, that would be about 15c -20c or so assuming 600 - 750m shares fully diluted, depending on whether the CHMO will have a chance to be converted. Anything is possible but at this stage I consider them to be lost.
Time will tell.
GLTA
CHM Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)